We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+7.26%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$263M
AUM Growth
+$1.92M
Cap. Flow
-$11.8M
Cap. Flow %
-4.49%
Top 10 Hldgs %
51.63%
Holding
68
New
8
Increased
22
Reduced
13
Closed
8

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$5.37M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.68M
3
AERI
Aerie Pharmaceuticals
AERI
+$3.67M
4
RDUS
Radius Health, Inc.
RDUS
+$3.63M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$2.63M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$7.83M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$6.37M
3
INCY icon
Incyte
INCY
+$6.36M
4
SHPG
Shire pic
SHPG
+$6.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$5.33M

Sector Composition

Rank Sector Weight
1 Healthcare 98.93%
2 Miscellaneous 1.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GWPH
51
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$922K 0.35%
9,200
– –
SUPN icon
52
Supernus Pharmaceuticals
SUPN
$2.57B
$902K 0.34%
20,953
-179,047
-90% -$6.37M
PCRX icon
53
Pacira BioSciences
PCRX
$1.03B
$762K 0.29%
16,000
– –
PVLA
54
Palvella Therapeutics
PVLA
$2.17B
$712K 0.27%
+1,763
New +$515K
TRIL
55
DELISTED
Trillium Therapeutics Inc.
TRIL
$693K 0.26%
161,069
-60,778
-27% -$336K
ASXC
56
DELISTED
Asensus Surgical, Inc.
ASXC
$625K 0.24%
68,391
– –
OMER icon
57
Omeros
OMER
$1.39B
$602K 0.23%
+30,239
New +$528K
GBT
58
DELISTED
Global Blood Therapeutics, Inc.
GBT
$561K 0.21%
20,500
-37,500
-65% -$1.12M
XNCR icon
59
Xencor
XNCR
$2.15B
$380K 0.14%
18,000
– –
ANAB icon
60
AnaptysBio
ANAB
$1.7B
– –
-100,500
Closed -$2.79M
BMY icon
61
Bristol-Myers Squibb
BMY
$137B
– –
-98,000
Closed -$5.33M
CHRS icon
62
Coherus Oncology
CHRS
$226M
– –
-62,000
Closed -$1.31M
NBIX icon
63
Neurocrine Biosciences
NBIX
$15.8B
– –
-40,264
Closed -$1.74M
NKTR icon
64
Nektar Therapeutics
NKTR
$2.55B
– –
-4,000
Closed -$1.41M
ONC
65
BeOne Medicines Ltd
ONC
$42.1B
– –
-66,041
Closed -$2.42M
ALDR
66
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-24,000
Closed -$498K
1 2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2017 Portfolio in Review

As of Q2 2017, International Biotechnology Trust held 68 positions worth $263M, up 0.73% from $261M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

International Biotechnology Trust withdrew a net $11.8M in Q2 2017, closing 8 positions and reducing 13 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $5.33M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, International Biotechnology Trust opened a new position in Viatris worth $5.43M.

  • International Biotechnology Trust's largest Q2 2017 buy was Viatris: 140,000 shares worth $5.43M.
  • International Biotechnology Trust added most to BioMarin Pharmaceuticals in Q2 2017, an estimated $3.68M increase.
  • International Biotechnology Trust's biggest Q2 2017 reduction was Illumina, cutting an estimated $7.83M.
  • International Biotechnology Trust fully exited Bristol-Myers Squibb in Q2 2017, selling an estimated $5.33M.
  • International Biotechnology Trust's ten largest holdings make up 52% of its $263M portfolio in Q2 2017.
  • International Biotechnology Trust opened 8 new positions and closed 8 in Q2 2017.
  • International Biotechnology Trust's portfolio value rose 0.73% quarter-over-quarter to $263M.

Based on International Biotechnology Trust's 13F filing for Q2 2017, filed 2 Mar 2018.